Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 1
2006 1
2011 1
2012 1
2013 1
2014 2
2015 1
2016 1
2017 1
2018 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Supporting Patients with Cancer after Dobbs v. Jackson Women's Health Organization.
Shuman AG, Aapro MS, Anderson B, Arbour K, Barata PC, Bardia A, Bruera E, Chabner BA, Chen H, Choy E, Conte P, Curigliano G, Dizon D, O'Reilly E, Tito Fojo A, Gelderblom H, Graubert TA, Gurtler JS, Hall E, Hirsch FR, Idbaih A, Ilson DH, Kelley M, La Vecchia C, Ludwig H, Moy B, Muss H, Opdam F, Pentz RD, Posner MR, Ross JS, Sacher A, Senan S, Perez de Celis ES, Tanabe KK, Vermorken JB, Wehrenberg-Klee E, Bates SE. Shuman AG, et al. Among authors: gurtler js. Oncologist. 2022 Aug 13;27(9):711-3. doi: 10.1093/oncolo/oyac165. Online ahead of print. Oncologist. 2022. PMID: 35962750 Free PMC article.
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study.
Dirix LY, Takacs I, Jerusalem G, Nikolinakos P, Arkenau HT, Forero-Torres A, Boccia R, Lippman ME, Somer R, Smakal M, Emens LA, Hrinczenko B, Edenfield W, Gurtler J, von Heydebreck A, Grote HJ, Chin K, Hamilton EP. Dirix LY, et al. Among authors: gurtler j. Breast Cancer Res Treat. 2018 Feb;167(3):671-686. doi: 10.1007/s10549-017-4537-5. Epub 2017 Oct 23. Breast Cancer Res Treat. 2018. PMID: 29063313 Free PMC article. Clinical Trial.
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial.
Schuler M, Yang JC, Park K, Kim JH, Bennouna J, Chen YM, Chouaid C, De Marinis F, Feng JF, Grossi F, Kim DW, Liu X, Lu S, Strausz J, Vinnyk Y, Wiewrodt R, Zhou C, Wang B, Chand VK, Planchard D; LUX-Lung 5 Investigators. Schuler M, et al. Ann Oncol. 2016 Mar;27(3):417-23. doi: 10.1093/annonc/mdv597. Epub 2015 Dec 8. Ann Oncol. 2016. PMID: 26646759 Free PMC article. Clinical Trial.
A phase 2, single-arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy.
Garcia JA, Hudes GR, Choueiri TK, Stadler WM, Wood LS, Gurtler J, Bhatia S, Joshi A, Hozak RR, Xu Y, Schwartz JD, Thompson JA. Garcia JA, et al. Among authors: gurtler j. Cancer. 2014 Jun 1;120(11):1647-55. doi: 10.1002/cncr.28634. Epub 2014 Feb 27. Cancer. 2014. PMID: 24577874 Free article. Clinical Trial.
Trabectedin as a single-agent treatment of advanced breast cancer after anthracycline and taxane treatment: a multicenter, randomized, phase II study comparing 2 administration regimens.
Goldstein LJ, Gurtler J, Del Prete SA, Tjulandin S, Semiglazov VF, Bayever E, Michiels B. Goldstein LJ, et al. Among authors: gurtler j. Clin Breast Cancer. 2014 Dec;14(6):396-404. doi: 10.1016/j.clbc.2014.06.006. Epub 2014 Aug 15. Clin Breast Cancer. 2014. PMID: 25239225 Clinical Trial.
A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer.
Zhu AX, Finn RS, Mulcahy M, Gurtler J, Sun W, Schwartz JD, Dalal RP, Joshi A, Hozak RR, Xu Y, Ancukiewicz M, Jain RK, Nugent FW, Duda DG, Stuart K. Zhu AX, et al. Among authors: gurtler j. Clin Cancer Res. 2013 Dec 1;19(23):6614-23. doi: 10.1158/1078-0432.CCR-13-1442. Epub 2013 Oct 2. Clin Cancer Res. 2013. PMID: 24088738 Free PMC article. Clinical Trial.
Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
Kemeny N, Garay CA, Gurtler J, Hochster H, Kennedy P, Benson A, Brandt DS, Polikoff J, Wertheim M, Shumaker G, Hallman D, Burger B, Gupta S. Kemeny N, et al. Among authors: gurtler j. J Clin Oncol. 2004 Dec 1;22(23):4753-61. doi: 10.1200/JCO.2004.03.119. J Clin Oncol. 2004. PMID: 15570076 Clinical Trial.